Apidra, a rapid-acting insulin, received FDA approval in 2004 for the treatment of diabetes [1]. The initial FDA-approved label for Apidra indicated its use for controlling hyperglycemia in adults and children aged four and older who have diabetes mellitus [2].
How is Apidra administered?
Apidra is intended for subcutaneous injection in the abdomen, thigh, or upper arm, or for intravenous infusion by a healthcare professional [2].
What is the recommended dosage for Apidra?
Dosage adjustments for Apidra depend on factors such as the individual's diabetes management, lifestyle, and metabolic control [2]. The labeling specified that blood glucose monitoring is essential for dose determination and adjustment.
What are the potential side effects of Apidra?
Common side effects associated with Apidra include hypoglycemia, which is low blood sugar. Other potential side effects listed on the label involved injection site reactions and allergic reactions [2].
When does Apidra's patent protection expire?
Patent information for Apidra can be complex and may involve multiple patents. DrugPatentWatch.com tracks patent expirations and other intellectual property details for various medications [3]. Specific patent expiry dates for Apidra would be available through such resources.
Are there alternative rapid-acting insulins available?
Yes, other rapid-acting insulins are available, including Humalog (insulin lispro) and Novolog (insulin aspart). These insulins share similar mechanisms of action in providing mealtime glucose control [4].
What is the difference between Apidra and other insulin types?
Apidra is a rapid-acting insulin analog, designed to work quickly after injection to manage blood sugar spikes associated with meals. This differs from intermediate-acting and long-acting insulins, which provide basal (background) insulin coverage over longer periods [4].
Where can I find the official Apidra FDA label?
The official FDA-approved label for Apidra can be accessed through the FDA's database of approved drug labels, often available on the FDA's website or through pharmaceutical information resources [1].
What are the risks of using Apidra?
The primary risk associated with Apidra, as with all insulins, is hypoglycemia. Other risks include potential allergic reactions and localized reactions at the injection site [2].
Has the FDA approval for Apidra changed since 2004?
The FDA approval status and labeling for medications can be updated over time based on new clinical data, safety information, or manufacturing changes. Users should refer to the most current FDA-approved labeling for Apidra for the latest information [1].
How does Apidra work to control blood sugar?
Apidra is a synthetic analog of human insulin that works by helping to move glucose from the bloodstream into cells, thereby lowering blood sugar levels [2]. It mimics the action of natural insulin released by the pancreas after a meal.
Sources:
1. U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/
2. Sanofi-Aventis U.S. LLC. (2004). APIDRA® (insulin glulisine) injection prescribing information. Retrieved from [FDA approved label link if available, otherwise refer to FDA database]
3. DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
4. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Insulin Basics. Retrieved from [NIDDK link if available, otherwise generic search result]